238 related articles for article (PubMed ID: 22022857)
1. Linagliptin for the treatment of type 2 diabetes (pharmacokinetic evaluation).
Scheen AJ
Expert Opin Drug Metab Toxicol; 2011 Dec; 7(12):1561-76. PubMed ID: 22022857
[TBL] [Abstract][Full Text] [Related]
2. Linagliptin plus metformin: a pharmacokinetic and pharmacodynamic evaluation.
Scheen AJ
Expert Opin Drug Metab Toxicol; 2013 Mar; 9(3):363-77. PubMed ID: 23373842
[TBL] [Abstract][Full Text] [Related]
3. Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a Phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjects.
Sarashina A; Sesoko S; Nakashima M; Hayashi N; Taniguchi A; Horie Y; Graefe-Mody EU; Woerle HJ; Dugi KA
Clin Ther; 2010 Jun; 32(6):1188-204. PubMed ID: 20637971
[TBL] [Abstract][Full Text] [Related]
4. Linagliptin: a novel dipeptidyl peptidase 4 inhibitor with a unique place in therapy.
Barnett AH
Adv Ther; 2011 Jun; 28(6):447-59. PubMed ID: 21603986
[TBL] [Abstract][Full Text] [Related]
5. Linagliptin, a dipeptidyl peptidase-4 inhibitor with a unique pharmacological profile, and efficacy in a broad range of patients with type 2 diabetes.
Forst T; Pfützner A
Expert Opin Pharmacother; 2012 Jan; 13(1):101-10. PubMed ID: 22149370
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of the potential for steady-state pharmacokinetic and pharmacodynamic interactions between the DPP-4 inhibitor linagliptin and metformin in healthy subjects.
Graefe-Mody EU; Padula S; Ring A; Withopf B; Dugi KA
Curr Med Res Opin; 2009 Aug; 25(8):1963-72. PubMed ID: 19552619
[TBL] [Abstract][Full Text] [Related]
7. Linagliptin, a xanthine-based dipeptidyl peptidase-4 inhibitor with an unusual profile for the treatment of type 2 diabetes.
Deacon CF; Holst JJ
Expert Opin Investig Drugs; 2010 Jan; 19(1):133-40. PubMed ID: 19947894
[TBL] [Abstract][Full Text] [Related]
8. Renal impairment has no clinically relevant effect on the long-term exposure of linagliptin in patients with type 2 diabetes.
Friedrich C; Emser A; Woerle HJ; Graefe-Mody U
Am J Ther; 2013; 20(6):618-21. PubMed ID: 23411609
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics, pharmacodynamics and tolerability of multiple oral doses of linagliptin, a dipeptidyl peptidase-4 inhibitor in male type 2 diabetes patients.
Heise T; Graefe-Mody EU; Hüttner S; Ring A; Trommeshauser D; Dugi KA
Diabetes Obes Metab; 2009 Aug; 11(8):786-94. PubMed ID: 19476474
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of dipeptidylpeptidase-4 inhibitors.
Scheen AJ
Diabetes Obes Metab; 2010 Aug; 12(8):648-58. PubMed ID: 20590741
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of Jentadueto® (linagliptin plus metformin).
Scheen AJ
Expert Opin Drug Saf; 2013 Mar; 12(2):275-89. PubMed ID: 23421949
[TBL] [Abstract][Full Text] [Related]
12. Effect of renal impairment on the pharmacokinetics of the dipeptidyl peptidase-4 inhibitor linagliptin(*).
Graefe-Mody U; Friedrich C; Port A; Ring A; Retlich S; Heise T; Halabi A; Woerle HJ
Diabetes Obes Metab; 2011 Oct; 13(10):939-46. PubMed ID: 21672124
[TBL] [Abstract][Full Text] [Related]
13. A randomized, open-label, crossover study to evaluate the pharmacokinetics of empagliflozin and linagliptin after coadministration in healthy male volunteers.
Friedrich C; Metzmann K; Rose P; Mattheus M; Pinnetti S; Woerle HJ
Clin Ther; 2013 Jan; 35(1):A33-42. PubMed ID: 23328275
[TBL] [Abstract][Full Text] [Related]
14. Linagliptin for the treatment of type 2 diabetes mellitus: a drug safety evaluation.
Barnett AH
Expert Opin Drug Saf; 2015 Jan; 14(1):149-59. PubMed ID: 25351273
[TBL] [Abstract][Full Text] [Related]
15. Clinical utility of the dipeptidyl peptidase-4 inhibitor linagliptin.
Grunberger G
Postgrad Med; 2013 May; 125(3):79-90. PubMed ID: 23748509
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic and pharmacodynamic evaluation of linagliptin in African American patients with type 2 diabetes mellitus.
Friedrich C; Glund S; Lionetti D; Kissling CJ; Righetti J; Patel S; Graefe-Mody U; Retlich S; Woerle HJ
Br J Clin Pharmacol; 2013 Sep; 76(3):445-54. PubMed ID: 23331248
[TBL] [Abstract][Full Text] [Related]
17. Linagliptin: a new DPP-4 inhibitor for the treatment of type 2 diabetes mellitus.
Toth PP
Postgrad Med; 2011 Jul; 123(4):46-53. PubMed ID: 21680988
[TBL] [Abstract][Full Text] [Related]
18. Assessment of the pharmacokinetic interaction between the novel DPP-4 inhibitor linagliptin and a sulfonylurea, glyburide, in healthy subjects.
Graefe-Mody U; Rose P; Ring A; Zander K; Iovino M; Woerle HJ
Drug Metab Pharmacokinet; 2011; 26(2):123-9. PubMed ID: 21084763
[TBL] [Abstract][Full Text] [Related]
19. Linagliptin and newer DPP-4 inhibitors: newer uses and newer indications.
Kalra S; Unnikrishnan AG; Agrawal N; Singh AK
Recent Pat Endocr Metab Immune Drug Discov; 2011 Sep; 5(3):197-202. PubMed ID: 21913883
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor linagliptin: a 4-week multicenter, randomized, double-blind, placebo-controlled phase IIa study in Japanese type 2 diabetes patients.
Horie Y; Kanada S; Watada H; Sarashina A; Taniguchi A; Hayashi N; Graefe-Mody EU; Woerle HJ; Dugi KA
Clin Ther; 2011 Jul; 33(7):973-89. PubMed ID: 21723606
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]